Overview

Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation

Status:
Completed
Trial end date:
2003-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effects of etanercept, and define the toxicity, when administered to patients with acute non-infectious lung injury (idiopathic pneumonia syndrome, IPS) and with subacute pulmonary dysfunction after allogeneic stem cell transplantation.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
FDA Office of Orphan Products Development
Treatments:
Etanercept